Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib - No Study Results Posted

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib (MACS0276)

This study is ongoing, but not recruiting participants.

Study NCT00756509 Information provided by Novartis

First Received: September 19, 2008 Last Updated: April 23, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	June 2012 (Final data collection date for primary outcome measure)